Assorted News from the Last Week:
Data shows that childhood cancer survivors were much more likely to develop an aging-associated health condition before the age of 65, with earlier onset, compared with the general population, according to a modeling study. Nearly all cancer treatments for children pose some short- or long-term risk for development of cardiovascular disease and that pediatric patients with cancer may be especially vulnerable to cardiovascular disease because of young age at treatment and expected long life span afterward. Childhood cancer survivors were also at greater risk of developing melanoma. High costs among factors in Malaysia behind childhood cancer patients from rural areas defaulting treatments. Researchers have developed a diagnostic platform that could classify brain tumors based on the body’s cancer-fighting immune response that harness the success of immunotherapies that revolutionized the treatment of childhood leukemias for childhood brain cancers. Support through healthcare institutional policies are key factors in pediatric oncology nurses’ efforts to provide a healing care environment for patients and their families. A rare joint effort launched by the Biden administration and embraced by the Trump White House brought two Palestinian children with cancer from Gaza to the U.S. for treatment this week, multiple sources tell NBC News. Upcoming Webinars, Online Opportunities, and Meetings: Wipe Out Kids’ Cancer (WOKC) is teaming up with 88 Jersey Mike’s Subs locations across DFW in March to raise funds in the fight against pediatric cancer. As part of Jersey Mike’s 15th Annual Month of Giving, the campaign will culminate on Wednesday, March 26, with 100% of all sales donated to WOKC in support of DFW kids (and their families) battling cancer. Click here for more information.Recent Recordings:
CAC2 member Mark Levine hosts a podcast called, “Help and Hope Happen Here” (available on Apple Podcasts, Spotify, and Google Podcasts). Access recent podcasts with CAC2 Members (and visit Help and Hope Happen Here for interviews with other CAC2 members and thought leaders from around the community):-
Joe McDonough (CAC2 Member Andrew McDonough B+ Foundation) and others speak about Audrey’s Children.
Take Action:
CAC2 Innovation Council Recommendation: ARYA-2 Clinical Trial for Pediatric Liver Cancer
Overview of the Opportunity: This request concerns a Phase 1/2 clinical trial, evaluating ET140203 T Cells in pediatric patients with relapsed/refractory Hepatoblastoma, Hepatocellular Neoplasm-Not Otherwise Specified, or Hepatocellular Carcinoma.
The Requester: Nicole Nunez, Associate Director of Patient Engagement and Regulatory Affairs (PhD), Eureka Therapeutics, Inc.
The Type of Request: Information sharing about a clinical trial opportunity for children with liver cancer. Sharing information about a trial does not imply that CAC2 is recommending or endorsing. Each patient should check with their medical professionals.
The Ask: Inform CAC2 Members about the ARYA-2 clinical trial (NCT04634357) which is a multi-center, Phase 1/2 clinical trial currently in the dose escalation phase, evaluating ET140203 T Cells in pediatric patients with relapsed/refractory Hepatoblastoma, Hepatocellular Neoplasm-Not Otherwise Specified, or Hepatocellular Carcinoma.
Please share the clinical trial flyer and help connect the trial team with any entities that can help bring awareness about this trial. Since pediatric liver cancer is an ultra rare disease (less than 200 kids diagnosed every year in the US), the trial team is doing everything it can to let doctors, patients and patient community groups know that this trial is open and actively recruiting.
Supporting Documentation: The trial is currently open at Dana-Farber Boston Children’s Cancer Institute, UCSF Benioff Children’s Hospitals, and Children’s Hospital Los Angeles. Autologous ET140203 T-cell therapy is designed to specifically target and destroy AFP/HLA-A2-positive liver cancer, while minimizing potential side effects traditionally associated with cancer treatment.
Eureka Therapeutics provides financial support for the patient and one caregiver to cover travel, food and accommodations during their participation in the trial.
Informational Flyer: https://drive.google.com/file/d/1fYAQL-yBVbzV4lv4xrKYEUQUmin7GR0R/view?usp=share_link
Patient friendly website at: www.eurekaconnectme.com
Corporate website is: www.eurekatherapeutics.com
For more information on the clinical trial, including details regarding eligibility criteria, please visit the clinicaltrials.gov website page: https://clinicaltrials.gov/study/NCT04634357
